A retrospective study of adverse event (AE) profile of rituximab and ocrelizumab in multiple sclerosis patients
Latest Information Update: 13 Oct 2021
At a glance
- Drugs Ocrelizumab (Primary) ; Rituximab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions
- 13 Oct 2021 New trial record